相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Blind prediction of response to erlotinib in early-stage non-small cell lung cancer (NSCLC) in a neoadjuvant setting based on kinase activity profiles.
R. Hilhorst et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer
Humberto Lara-Guerra et al.
LUNG CANCER (2012)
Early Prediction of Nonprogression in Advanced Non-Small-Cell Lung Cancer Treated With Erlotinib By Using [18F]Fluorodeoxyglucose and [18F]Fluorothymidine Positron Emission Tomography
Thomas Zander et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non-Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial
Jean-Yves Douillard et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Is F-18-FDG PET/CT Useful for the Early Prediction of Histopathologic Response to Neoadjuvant Erlotinib in Patients with Non-Small Cell Lung Cancer?
Tjeerd S. Aukema et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Phase II Study of Preoperative Gefitinib in Clinical Stage I Non-Small-Cell Lung Cancer
Humberto Lara-Guerra et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Computed tomography response, but not positron emission tomography scan response, predicts survival after neoadjuvant chemotherapy for resectable non-small-cell lung cancer
Tawee Tanvetyanon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Lymph node isolated tumor cells and micrometastases in pathological stage I non-small cell lung cancer: prognostic significance
Ottavio Rena et al.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2007)
Cancer care Ontario and American society of clinical oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non-small-cell lung cancer guideline
Katherine M. W. Pisters et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
New molecularly targeted therapies for lung cancer
Sophie Sun et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
The IASLC lung cancer staging project: Proposals for the revision of he TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours
Peter Goldstraw et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
The IASLC lung cancer staging project: Proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer
Valerie W. Rusch et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression:: A phase III trial in non-small-cell lung cancer
Manuel Cobo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review
David Gilligan et al.
LANCET (2007)
We should desist using RECIST, at least in GIST
Robert S. Benjamin et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer
N. van Zandwijk et al.
ANNALS OF ONCOLOGY (2007)
Effects of smoking on the pharmacokinetics of erlotinib
M Hamilton et al.
CLINICAL CANCER RESEARCH (2006)
Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer
CJ Hoekstra et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen
JR Johnson et al.
CLINICAL CANCER RESEARCH (2005)
Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer
T Winton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Adjuvant chemotherapy in completely resected non-small-cell lung cancer
KMW Pisters et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients
A Haringhuizen et al.
ANNALS OF ONCOLOGY (2004)
CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: A quantitative analysis correlated with FDG PET findings
H Choi et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer
GV Scagliotti et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Prognostic impact of micrometastatic tumor cells in the lymph nodes and bone marrow of patients with completely resected stage I non-small-cell lung cancer
T Osaki et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Assessment of lung cancer response after nonoperative therapy: Tumor diameter, bidimensional product, and volume. A serial CT scan-based study
M Werner-Wasik et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2001)
分享论文
